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Addressing the double-burden of diabetes
and tuberculosis: lessons from Kyrgyzstan
Jolene Skordis-Worrall1* , Jeff Round2, Matthias Arnold3,4, Aida Abdraimova5, Baktygul Akkazieva5 and
David Beran6
Abstract
Background: The incidence of diabetes and tuberculosis co-morbidity is rising, yet little work has been done to
understand potential implications for health systems, healthcare providers and individuals. Kyrgyzstan is a priority
country for tuberculosis control and has a 5% prevalence of diabetes in adults, with many health system challenges
for both conditions.
Methods: Patient exit interviews collected data on demographic and socio-economic characteristics, health
spending and care seeking for people with diabetes, tuberculosis and both diabetes and tuberculosis. Qualitative data
were collected through semi-structured interviews with healthcare workers involved in diabetes and tuberculosis care,
to understand delivery of care and how providers view effectiveness of care.
Results: The experience of co-affected individuals within the health system is different than those just with tuberculosis
or diabetes. Co-affected patients do not receive more care and also have different care for their tuberculosis than people
with only tuberculosis. Very high levels of catastrophic spending are found among all groups despite these two
conditions being included in the Kyrgyz state benefit package especially for medicines.
Conclusions: This study highlights that different patterns of service provision by disease group are found. Although
Kyrgyzstan has often been cited as an example in terms of health reforms and developing Primary Health Care, this
study highlights the challenge of managing conditions that are viewed as “too complicated” for non-specialists and
the impact this has on costs and management of individuals.
Keywords: Tuberculosis, Diabetes, Health systems, Catastrophic spending, Co-morbidity
Background
According to the World Health Organization (WHO),
the world is on track to meet the target of a 50% mortality
reduction of tuberculosis (TB) [1], but new challenges
such as diabetes are challenging this progress [2]. With 6%
of TB cases worldwide attributable to diabetes [3], there is
the need to bridge the management of diabetes and TB
from a health system perspective [4]. Looking at diabetes
and TB from the population perspective can be seen as a
double burden of disease, with the same population being
affected by both conditions. However, at an individual
level this is an issue of multi-morbidity/co-morbidity and
the challenge this represents for the individual and the
health system for management [5].
A WHO collaborative framework on diabetes and TB
designed to help policy-makers, public health specialists
and healthcare workers address the joint burden of dia-
betes and TB calls for improved collaboration between
diabetes and TB programs, as a part of the broader agenda
in strengthening health systems [6]. It describes how past
successes in coordination and collaboration between TB
and HIV/AIDS programs can be used as a model.
The confluence of diabetes and TB is likely to exacerbate
global health inequities and possibly also threaten nascent
economic growth in these regions. Low and middle-income
countries:
 account for the majority of the world’s population [7]
 have the highest burdens of both diabetes and TB [8]
 are likely to experience a rapidly rising incidence of
diabetes by 2030 [9]
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 have health systems organized for acute rather than
chronic care [10]
 have health systems already challenged by double or
triple disease burdens [11] and
 face increasing funding pressures, as health spending is
not expected to increase faster than in other countries
despite the expected increase in disease burden [12]
Given these challenges, there is a need for studies to
examine the joint medical costs of managing both condi-
tions. Kyrgyzstan, located in Central Asia, is a former
Soviet Republic with a population of 5·4 million. Life-
expectancy at birth is 66 years for men and 73 years for
women [13] and has been rising steadily rising since
1960 [14]. It is defined by the World Bank as a low in-
come country [15] and is one of the 18 priority countries
in the WHO EURO region for TB control [16]. Data
from the National TB center shows a national preva-
lence of 190 per 100,000 in 2013 with a mortality rate of
11 per 100,000 [17]. In Bishkek, the capital city, there is
a prevalence of 131.7 per 100,000 population and mor-
tality rate of 18·1 per 100,000 [17]. This is compared to
a prevalence of 73 and mortality rate of 5·1 per 100,000
population respectively in the WHO EURO Region [18].
Kyrgyzstan also has the second highest prevalence of
multi-drug resistant TB (MDR TB) among new cases in
the European region (at 36.6%) and the highest prevalence
of MDR TB among previously treated cases (82.0%). Pre-
viously treated cases of TB account for 15.7% of all TB
cases, a phenomenon that the WHO suggests may be
indicative of clinical failures, the need for additional
programme management and possible reinfection and/
or misclassification [19]. The International Diabetes
Federation estimates a 5·0% prevalence of diabetes in
those aged 20 to 79 years in Kyrgyzstan, which is ex-
pected to increase to 6·6% by 2035 [20]. Previous work
has shown a high number of undiagnosed people with
diabetes as well as weak capacity to respond to the
needs of people with diabetes [21].
Kyrgyzstan thus constitutes an ideal case study for
trying to examine the barriers to the joint manage-
ment of diabetes and TB, without the significant con-
founding of HIV/AIDS found in other low-income
settings. Highly centralized, vertical TB control pro-
grams inherited from the Soviet system, such as those
in Kyrgyzstan, are difficult to integrate with the gene-
ral health services because of insufficient funding,
sub-optimal allocation of available resources, poorly
developed primary health care services and, often, psy-
chological resistance on the part of TB specialists [22].
The aim of this paper is to examine the joint manage-
ment of diabetes and TB from the demand and supply
side of the health system, to highlight challenges in
the management of these conditions.
Methods
Ensor and Cooper [23] define demand-side barriers as
those that control decisions made by the community,
household and individual. Supply-side factors are those
that are linked to the provision of healthcare and the
health system, and LMICs may struggle with to deliver
care in the face of rising costs and cost-containment
strategies [24]. The demand for healthcare is influenced
by whether or not an individual realizes they are sick
and are then “willing and able to seek appropriate health-
care” [23]. This in turn is influenced at the individual and
household level by such factors as age, sex, education, in-
come and whether the individual identifies illness and is
willing and able to seek appropriate health care. The diag-
nostic groups and self assessed health status as measured
by the multidimensional SF8 index of physical and mental
health, will give an indication of need for services [25, 26].
Utilization will be measured using proxy indicators in-
cluding: Health spending and the number of care-seeking
visits in the last 90 days. Using data from the interviews
with health service providers will provide the context for
what the health system “supplies” to meet the demand of
people with either diabetes and/or TB. The analytical
framework adopted is presented in Fig. 1.
Quantitative data were collected from individuals
adapting a questionnaire used to collect data on TB care
seeking in Cape Town, South Africa [27]. The question-
naire was translated from English to Russian and then
back-translated to ensure accuracy and coherence and
collected the following data:
 Demographic and socio-economic characteristics
 Self reported health status as measured by the SF8,
the short form of the SF36 measure of self-reported
health
 Direct and indirect, formal and informal treatment
costs
The quantitative patient questionnaire was administered
at the main facilities in Bishkek where diabetes and TB
care would be delivered by trained health systems re-
searchers. Ethical clearance was obtained from University
College London (Project 0025/001) and locally. Interview
days were randomly selected over a given time period and
all individuals attending the clinic on those days were in-
vited to participate in the study.
Quantitative data were analyzed in Stata Version 12.
Descriptive statistics are reported using pairwise com-
parison of means to test for differences. A linear regres-
sion model is fit for continuous dependent variables,
while logistic regression is used for binary dependent
variables. We control for sex, age, level of education and
income in all models. Robust standard errors were esti-
mated using bootstrapping to account for skewness in
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the continuous resource use and cost variables and to
adjust for heteroskedacity in the logit models. All signifi-
cant differences are calculated at the 95% confidence level.
Health expenditure is calculated as the costs of trans-
portation to a health facility, the formal cost of the con-
sultation and all other formal costs occurring at the
point of care including diagnostic tests, any unofficial
costs paid at the point of care, and any drug costs re-
lated to the care seeking event that may not have been
incurred at the point of care. For hospital-based care,
costs were collected for the most recent overnight ad-
mission, observation room and routine outpatient visit
occurring during the reference period. Costs were col-
lected for the most recent instance of care seeking only,
to reduce recall bias. To measure total expenditure in
the last 90 days, these costs were multiplied by the num-
ber of times respondents reported visiting that provider
in the last 90 days. Catastrophic health care spending is
considered, based on the percentage of monthly income
spent on medical care. Health spending is described as
catastrophic in this study if it equaled or exceeded 10%
of total household income [28–30]. This threshold is
used as this has been viewed as the level when house-
holds are forced to sacrifice other basic needs, sell assets,
incur debt or enter poverty [31]. The costs of seeking
care outside of a hospital do not include unofficial costs,
and only capture the cost of one care seeking episode
per non-hospital provider in the last 90 days i.e. respon-
dents were not asked how many times they visited that
provider in the last 90 days. As such the costs of non-
hospital care seeking are likely to be highly conservative
but they are included here for completeness. The SF-8
physical and mental health subscales are used as a
measure of health care need.
Qualitative data from health service providers were
collected using a tool adapted from the Rapid Assess-
ment Protocol for Insulin Access (RAPIA) in Kyrgyzstan
[32]. This required semi-structured interviews with
healthcare workers involved in both diabetes and TB
care. The aim of these interviews was to identify possible
health system barriers and triangulate with quantitative
data. Eight healthcare workers were interviewed from fa-
cilities identified by local partners as most likely to treat
people with diabetes, TB and both conditions. Each
interview lasted on average 45 min. Responses were en-
tered into a spreadsheet and translated to English for
analysis. In parallel a review of the literature was carried
out to provide background information on the situation
of diabetes and TB in Kyrgyzstan. The responses from
the questionnaires were analyzed thematically focusing
on gaining information about TB and joint management
of diabetes and TB management building on data
already collected and analyzed in a similar way just for
diabetes [21, 32].
The qualitative and quantitative data were initially
analyzed independently so as to limit any contamination
of, or bias in, the results. Once initial findings had been
summarized, the quantitative data was used to highlight
questions to be asked of the qualitative findings. The
aims of those questions were generally to enhance the
overall understanding of phenomena observed in the in-
dividual data.
Results
As described in Table 1, 138 (44·7%) of the sample had
been diagnosed with either Type 1 or Type 2 diabetes,
139 (45·0%) with TB but not with diabetes, and 32
(10·4%) with both diabetes and TB. Although the total
Fig. 1 Analytical framework
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sample was predominantly female (58·3%), co-affected
respondents were significantly more likely to be male and
better educated on average. Individuals with TB were sig-
nificantly younger than both other groups and people with
diabetes lived in smaller households than did the other
two groups. These data are summarized in Table 2, where
it is worth noting that despite co-affected individuals
appearing to have a much lower household income than
the other groups, the wide variance in the income data re-
sult in that difference being non-significant.
TB services in Kyrgyzstan are delivered at all levels of
the health system [33]. At the Republican (National) level
the TB program is managed by the National Phthisiology
Centre, Republican Rehabilitation Centre and the Repub-
lican TB Hospital. At Oblasts (Regions) the management of
TB is done by TB control centers, hospitals; and finally at
the level of the Rayons (Districts) by Rayon and Inter-
Rayon TB hospitals and dispensaries. Private providers
in Kyrgyzstan are not allowed to deliver care for TB
and people with the condition should be referred to a
specialized facility. As TB is a large problem in the
prison population (prevalence: 1767·0; mortality 430·1
per 100,000) the Department of Corrections under the
Ministry of Justice is also a provider of care for TB
[33]. Diabetes care is provided at Rayon, Oblast and
National level [21, 32]. However, varying patient pathways
were found for people with diabetes especially if they re-
quired insulin. In looking at the organization of diabetes
and TB care as one doctor described it there is a “Lack of
integration between the two services”. To highlight this,
another doctor from one of the TB specialized facilities
described this as “Endocrinologist treats diabetes and we
treat TB”. All doctors interviewed highlighted this silo
approach or as one doctor described it “parallel” care for
people with both diabetes and TB.
Each specialty, diabetes or TB, called the other spe-
cialty when needed. Joint consultations were sometimes
described, but both conditions were treated in specialist
facilities or wards. The choice of admitting someone
with diabetes and TB to TB or diabetes wards was based
on how “dangerous” the individual is. The way this was
viewed was that whichever condition was seen as more
serious is prioritized. TB care is provided on an inpatient
basis with people being admitted for 2–3 months and
then discharged and receiving a further 4 month out-
patient treatment. Diabetes care in Bishkek was mainly
provided either at Family Medicine Centers (FMC) or
through the Endocrinology Dispensary. For diabetes
every year one or two inpatient stays at different levels
of the health system are planned for patients.
Co-affected individuals should be receiving equivalent
care for each of their illnesses, which is not found. The
majority of care seeking reported by respondents, took
place in a hospital environment. Although the patient
survey asked about care seeking from specialists, general
practitioners, pharmacists, clinics and other providers
outside of the hospital environment, 86.1% of respondents
had not sought any form of care outside of a hospital in
the preceding 90 days. Of those who did seek care outside
of a hospital, 72.1% were people with diabetes (0% co-
affected) and 67.4% of those visits were to specialist
doctors, while 23.3% were to pharmacists or medicine
dispensaries. Individuals with TB only were less likely
than people with diabetes only or co-affected individ-
uals to use a hospital drug dispensary or have an out-
patient visit, but more likely than individuals with only
diabetes to have any contact with the hospital. No dif-
ferences were observed between groups for emergency
care visits (Table 4).
This difference may also be explained by funding for
TB. In an analysis of the National Health Accounts,
funding for TB in Kyrgyzstan is financed 55% by the
state budget and 44% by external donors [33]. The
remaining 1% is out of pocket payments. In comparison
Table 1 Sample size
Illness category Frequency Percentage (%)
Co-affected (TB and diabetes) 32 10.4
Diabetes (Type 1 or Type 2) 138 44.7
TB 139 45.0
Total 309 100.0
Table 2 Demographic characteristics
Co-affected Diabetes TB affected Total
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Gender Ratio (Male/Female) 1.67 (0.62) 0.42 (0.08) 0.99 (0.17) 0.72 (0.08)
Age 53.91 (10.85) 54.68 (13.17) 30.28 (12.79) 43.62 (17.56)
Educationa 3.63 (0.56) 3.49 (0.63) 3.26 (0.55) 3.4 (0.60)
Household Size 4.41 (1.88) 3.33 (2.28) 4.13 (1.91) 3.8 (2.12)
Household Income KGSb 4941 (4459) 6281 (7524) 8535 (15302) 7156 (11568)
aEducation is measured as a categorical variable with “1 = no schooling”, “2 = completed primary school”, “3 = completed secondary school” and “4 = completed
tertiary education”
bKGS = Kyrgyz Som: US$ 1.00 = KGS 46.01 (at average 2011 exchange rate)
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diabetes does not receive any direct external funding.
About US$ 2–3 million spent on diabetes supplies repre-
senting 1.4-2.0% of total expenditure on health [32]. Over-
all 6.5% of total public spending and 18% of external
support was spent on TB. Forty percent of all funds allo-
cated for TB in Kyrgyzstan are allocated to inpatient facil-
ities in comparison to 3% for outpatient facilities. The
doctors interviewed stated that medicines and care should
be free for both conditions. Donors supply medicines for
TB, whereas the government does this for diabetes.
All medicines for TB are treatment based on Direct
Observed Treatment Short course (DOTS) and DOTS
plus programs. and provided through external donors.
DOTS is available to all newly diagnosed TB cases
throughout Kyrgyzstan and the DOTS plus program is
limited to some areas of Kyrgyzstan. Pre-qualified medi-
cines are supplied to Kyrgyzstan mainly through the
Global Fund and some government funds. With regards
to diabetes poor purchasing practices were found leading
to many people needing to purchase some or all of their
medicines in the private sector [21]. This was not the
case for insulin.
People may not have to pay for their TB medicines,
but for other medicines that may be prescribed e.g. vita-
mins, which are not provided for free. However, financial
barriers exist with regards to paying for transportation
from FMC to facility where the person is referred to and
especially for outpatient management of TB. Others also
mentioned administrative issues acting as a barrier with
referrals for people with diabetes and TB. Similar chal-
lenges we also found for people with diabetes in the pre-
vious study [32].
From the questionnaire we find that individuals with
only TB are less likely than people with only diabetes to
spend anything in order to access care and in particular
are less likely to spend on outpatient care or on drugs
(Table 3). The overall monthly spend of people with only
TB was also less than that of people with only diabetes,
as is the monthly spend on drugs. People with diabetes
were more likely than co-affected individuals to have
spent money on drugs. No other differences were found
in the probability of spending on care or in the value of
spending on care between the groups (Table 4). People
with diabetes spend the most overall and the cost of
medicines is the largest portion of total spending for all
groups. The differences found in the exit interviews may
reflect the fact that people with TB receive their drugs as
inpatients and do not have to pay separately for those
drugs, or make separate outpatient visits to collect those
drugs, whereas this may not be the case for diabetes
impacting co-affected individuals.
Access to diagnostic tools for TB was not seen as
problematic by the doctors interviewed and this asser-
tion could not be tested with the quantitative data from
Table 3 Summary of results
Co-affected Diabetes Tuberculosis
Well-being Mean (SE) Mean (SE) Mean (SE)
SF-8 Physical component 35.39 (1.12) 34.43 (0.86) 38.94 (0.95)
SF-8 Mental component 37.41 (1.26) 43.67 (0.74) 41.40 (0.91)
Probability of resource use Probability (SE) Probability (SE) Probability (SE)
Any hospital visit 0.84 (0.07) 0.64 (0.04) 0.89 (0.02)
Any ER/A&E visit 0.13 (0.06) 0.06 (0.02) 0.14 (0.03)
Hospital drug dispensary use 0.81 (0.07) 0.77 (0.04) 0.35 (0.04)
Any outpatient visit 0.94 (0.04) 0.95 (0.02) 0.69 (0.04)
Probability of spending on resource Probability (SE) Probability (SE) Probability (SE)
Any spending 0.44 (0.09) 0.64 (0.04) 0.42 (0.04)
Any drug spend 0.38 (0.09) 0.55 (0.04) 0.33 (0.04)
Any hospital spending 0.09 (0.05) 0.03 (0.01) 0.07 (0.02)
Any outpatient spending 0 0.20 (0.03) 0.08 (0.02)
Probability catastrophic 0.19 (0.07) 0.31 (0.04) 0.08 (0.02)
Total monthly spending (K$) Mean (SE) Mean (SE) Mean (SE)
All monthly spend 837 (305) 996 (193) 424 (77)
Percent of monthly income 21.90 (9.03) 32.16 (8.76) 8.09 (2.28)
Monthly drug spend 613 (213) 509 (76) 207 (38)
Monthly Hospital spending 224 (194) 192 (114) 141 (55)
Monthly outpatient spending 0 295 (135) 75 (30)
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TB patients. However, the doctors interviewed stated
that some people have to pay for their chest x-rays. For
diabetes it was found that there were problems with the
availability of some laboratory tools and that HbA1c was
only available in the private sector [32]. Problems with
access to some diagnostic tools for diabetes e.g. blood
glucose meters and strips at TB facilities were noted, but
basic blood chemistry was available. The quantitative
survey asked patients how much they had paid for dia-
betes test strips. More than a third (35%) of diabetic pa-
tients had paid for diabetes test strips, indicating that
they had been purchased outside of the public health
care system.
As described by one doctor “Narrowly focused
specialization complicates management of patients”.
This focus on one condition versus another was
highlighted through quotes from both a diabetes and TB
specialist when they respectively said “We treat diabetes
and that’s it” and “Since our main task is TB treatment,
the primary treatment is focused on TB. And then we
treat the co-morbidity”. All doctors interviewed con-
firmed this by saying that endocrinologists lacked know-
ledge of TB and TB specialists lacked knowledge of
diabetes. In addition it should be noted that for diabetes
it was often said that General Practitioners were not able
to treat diabetes and that they were “scared” of treating
diabetes, especially using insulin [32]. There has been
training in TB management in Kyrgyzstan funded by the
Global Fund, but this training focused on TB and HIV/
AIDS. Issues around lack of knowledge of TB at lower
levels of the health system were mentioned by specialists
in that often there were problems identifying TB at
FMCs. For diabetes management training had been car-
ried out, but many stated that the challenge was then in-
tegrating this into daily clinical practice [32]. These
factors may explain why despite requiring “double” care
for their diabetes and TB, co-affected individuals actually
receive less due to the lack of training and vertical man-
agement of the two diseases.
Good TB management is needed for good diabetes
management and vice versa. But the challenge, as stated
by some of the doctors interviewed, was that people with
TB require more food and this is not advisable for
people with diabetes. Also TB treatment is focused on
inpatient care and “After 2–3 months of treatment,
when they complete the intensive treatment phase, start
feeling well [they] stop considering themselves as pa-
tients.” So the main problem with adherence is when
Table 4 Pairwise comparisons of well-being, service use and spending
Diabetes v co-affected Tuberculosis v co-affected Tuberculosis v diabetes
Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI)
Well-being
SF-8 Physical component −0.966 (−5.720 to 3.788) 3.548 (−1.203 to 8.299) 4.514 (1.602 to 7.425)***
SF-8 Mental component 6.254 (1.843 to 10.665)** 3.982 (−0.426 to 8.390) −2.272 (−4.973 to 0.430)
Probability of resource use
Any hospital visit −0.177 (−0.361 to 0.006) 0.048 (−0.135 to 0.231) 0.225 (0.113 to 0.338)***
Any ER/A&E visit −0.067 (−0.205 to 0.071) 0.012 (−0.127 to 0.150) 0.079 (−0.006 to 0.163)
Hospital drug dispensary use −0.044 (−0.250 to 0.162) −0.467 (−0.673 to −0.261)*** −0.423 (−0.549 to −0.297)***
Any outpatient visit 0.012 (−0.151 to 0.175) −0.247 (−0.410 to −0.084)*** −0.259 (−0.359 to −0.159)***
Probability of spending on resource
Any spending 0.200 (−0.026 to 0.427) −0.020 (−0.247 to 0.206) −0.220 (−0.359 to −0.082)**
Any drug spend 0.176 (−0.049 to 0.401) −0.044 (−0.269 to 0.181) −0.220 (−0.357 to −0.082)**
Any hospital spending −0.065 (−0.170 to 0.041) −0.022 (−0.127 to 0.083) 0.043 (−0.022 to 0.107)
Any outpatient spending 0.196 (0.047 to 0.345)** 0.079 (−0.070 to 0.228) −0.112 (−0.207 to −0.025)**
Total monthly spending (K$)
All monthly spend 269 (−236 to 774) −189 (−694 to 316) −458 (−768 to −149)**
Monthly drug spend 56 (−165 to 277) −182 (−403 to 39) −238 (−374 to −103)***
Monthly Hospital spending 25 (−264 to 313) −39 (−327 to 249) −63 (−240 to 113)
Monthly outpatient spending 188 (−131 to 507) 31 (−288 to 350) −157 (−352 to 39)
Catastrophic spending
Percent of monthly income 10.62 (−10.56 to 31.81) −6.50 (−27.73 to 14.74) −17.12 (−30.47 to −3.77)**
Probability catastrophic 0.121 (−0.060 to 0.303) −0.113 (−0.295 to 0.069) −0.234 (−0.349 to −0.120)***
*Significant at 0.05 **Significant at 0.01 ***Significant at 0.001
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people are discharged from hospital. As people with dia-
betes and TB need to adhere to two sets of indications
and medicines, that may be contradictory, this may im-
pact their use of the health system. In addition cost of
treatment may impact adherence and the assessment of
catastrophic health payments in the total sample, and
comparisons of catastrophic spending between groups
found that 20.1% of the total sample spent catastrophic-
ally on their healthcare, with households spending an
average of 11.8% of total household income on health-
care (Table 3). People with only TB were less likely to
incur catastrophic spending than people with only dia-
betes, while at the same time spent a lower percentage
of their monthly income on care (Table 4).
Discussion
Very different patterns of service utilization by disease
group are found. Individuals with TB receive significantly
more inpatient care and less outpatient care than the
other two groups. People with diabetes have significantly
more outpatient visits than people with TB. Co-affected
individuals have the most visits to health centers to collect
medication, followed by people with diabetes and people
with TB. This pattern of service use, when compared with
health need, raises two important questions with respect
to the sufficiency, equity and efficiency of care. Firstly, co-
affected individuals have significantly worse mental health
scores than the other two groups and suffer from two dis-
eases, but they neither receive more inpatient care nor
more outpatient care than the other two groups. Further-
more, the doctors responding mentioned nothing about
additional services for individuals co-affected by both dis-
eases. This suggests that care for people affected by both
diseases may be under-provided. Secondly, co-affected in-
dividuals have TB, but do not appear to receive the same
inpatient-based treatment for their TB as do people af-
fected by TB only. If inpatient care for TB is the more
effective form of care in this context, then co-affected in-
dividuals are being treated with less effective care and this
would be inequitable. If however, outpatient care is as
effective as inpatient care in this context, then it is tech-
nically inefficient to provide inpatient-based care to indi-
viduals affected by TB alone. This highlights the challenge
emphasized by Riza et al. [34] of what models of care are
needed for the co-management of diabetes and TB.
Although medicines and care for both conditions should
be free, as they are covered by the State Guaranteed
Benefit Package, our results show significant spending on
drugs and care, often at catastrophic levels – co-payments
often occur in LMIC even where treatment should be
provided free at the point of access [35]. That said it is
worrying to see the low levels of spending by co-affected
individuals, as it would be expected they would spend
more than individuals with only one condition.
The analytical framework outlined in Section 1 is sim-
plistic but assisted in linking the concepts of need, ser-
vice use and service provision in order to reflect on the
sufficiency, equity and efficiency of care for individuals
co-affected by diabetes and TB. This study has a few
limitations in terms of different aspects of its method-
ology and findings. The interviews on the possible health
system barriers were only carried out with 8 doctors and
focused on the experience of individuals in Bishkek and
not all of Kyrgyzstan. The tool used was an adaptation
of an existing tool used for diabetes and may not have
been able to capture all aspects of TB management.
Parts of the results rely on published studies to fill in
certain gaps versus having collected this information
first hand. This study claims to provide insight into un-
met need for care, but collecting data from patient exit
interviews will bias the data towards people who are able
to access some form of care. In addition, the very small
sample of co-affected individuals has resulted in wide
confidence intervals around measure of household in-
come and health spending particularly. This may have
resulted in large differences in income and expenditure
showing as not statistically significant. That said, the use
of multiple measures of need and multiple measures of
care use, do indicate robustly, that co-affected individuals
are receiving less care than people with lower or equiva-
lent need. Despite these limitations to the authors’ know-
ledge this is the first study of its kind to look at financial
and health system barriers for the co-management of
diabetes and TB.
Conclusion
Kyrgyzstan has been cited as an example in terms of health
reforms and developing Primary Health Care [36], however
this study highlights the limits of this success in managing
conditions that are viewed as “complicated” thus requiring
specialist management. Verticalization of the health system
impacts patient outcomes as well as health system targets
for TB control. In many countries such as Kyrgyzstan, the
link between TB and HIV is smaller than diabetes and TB
[37, 38] and this will require a shift in a variety of health
system factors including: healthcare provision and treat-
ment guidelines; organization of the health system; govern-
ment priorities and donor perspectives. This study shows
that the WHO Collaborative Framework for Care and
Control of Tuberculosis and Diabetes are in need of imple-
mentation at country level especially with regards to their
aim of strengthening collaboration between diabetes and
TB services [4]. Although a lot of emphasis in this frame-
work is put on case detection, there is the need to guaran-
tee quality management of diabetes and TB to ensure that
the focus of the health system’s response is not the manage-
ment of the individual conditions, but the management of
the individual.
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